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Donor alloreactive T cells are required for tGVHD and damage the thymus 


















Clinical GVHD correlates with tGVHD and thymic function of B6 → BALB/c (8.5 Gy) mice. (A) Weight loss and (B) GVHD score. n = 6–7/group. (C) 
Donor BM-derived CD4+CD8+ thymocyte numbers on day 22. Dots represent groups of animals. *P < 0.05 versus TCD-BM control. n = 6–7/group. 
(D) Total donor splenic T cells on day 22. *P < 0.05, **P < 0.001 versus control; P values are shown for donor BM-derived T cells. n = 6–7/group. 
(E) Proliferation of splenic T cells after stimulation with anti-CD3 and anti-CD28 on day 22. *P < 0.05, **P < 0.001 versus control. TCD-BM only 
and 0.25 × 105 T cells, n = 12; 0.5 × 105 T cells, n = 6; 1 × 105 T cells, n = 3. (F) Linear regression of log-transformed thymic cellularity versus 
log-transformed splenic RTE numbers. Squares represent individual animals combined (n = 24) across all groups. One of two identical experi-
ments is shown. r, regression coefficient. (G) RTEs versus the dose of donor T cells on day 42 after transplant. Dots represent individual animals. 
n = 4–5/group. *P < 0.05 versus recipients of TCD-BM only. (H) Histopathology (H&E) of paraffin-fixed thymus sections on day 28 (no GVHD, BM 
only; GVHD, BM plus 0.25 × 106 WT T cells). The dotted line indicates the corticomedullary junction. C, cortex; M, medulla. Original magnifica-
tion, ×50. n = 5/group. Representative sections are shown. (I) Quantification of cortical area (% of total area) on day 28. Average of 3 sections of 
each organ (50 μm apart). Symbols represent individual animals. n = 4–7/group. *P = 0.01 versus recipients of TCD-BM only. All horizontal bars 
indicate the mean. All values are mean ± SEM.
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Recipients of low doses of donor alloreactive T cells exhibit tGVHD 



























GVHD damages thymic architecture, thymic output, and negatively influ-












































Quantification of thymic cortical area
	 BM	only	 T	cells
	 	 0.5	×	105	 1	×	105	 2.5	×	105
No. of thymi analyzed 5 of 5 9 of 9 7 of 9A 4 of 9A
Loss of corticomedullary  0 0 2 5
 junction (n)
Mean cortical area (%) 73.8 70.1 63.6B 52.7B
SD 2.9 5.5 6.2 9.4
SEM 1.3 1.7 2.4 4.7
ASome thymi were not analyzed because loss of corticomedullary junction pre-
cludes accurate determination of the cortical and medullary areas. BP < 0.05 
versus TCD-BM only.
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thymic  damage  in  allo-BMT  recipi-
ents, which is associated with specific 




Donor alloreactive T cells rapidly infil-
trate the thymus after allo-BMT and 
become profoundly activated. To assess 


















Alloreactive T cells quickly infiltrate the thymus, undergo proliferation, and display an activated 
phenotype. (A) In vivo bioluminescence imaging (BLI) of alloreactive T cell (0.25 × 106) migration 
after transplant. Ex vivo imaging of the thymus confirmed donor T cell infiltration on day 6. Rep-
resentative images from 1 of 2 identical experiments are shown. (B) Percentages of proliferating 
alloreactive (CFSEdim) and nonproliferating (CFSEhi) infiltrating donor T cells as well as donor central 
memory (Tcm, CD44hiCD62Lhi) and effector memory (Tem, CD44hiCD62Llo) T cells as a fraction of 
all leukocytes (CD45+ cells). n = 14/group, combined from 2 identical experiments (mean ± SEM). 
*P < 0.05 allogeneic (allo) versus syngeneic (syn). (C) Infiltrating donor T cells in the thymus and 
spleen (mean ± SEM) at days 7, 14, 21, and 28 in BALB/c (allogeneic) or B6 (syngeneic) recipients. 
n = 14–15/group, combined data from 1 to 4 identical experiments (mean ± SEM). (D) FoxP3+ T cells 
derived from infused donor T cells are shown as a percentage of all donor-infused Thy1.1+CD4+ 
T cells in thymus and spleen at day 28 after allogeneic and syngeneic BMT. **P < 0.01 allogeneic 
versus syngeneic groups. n = 14, syngeneic; n = 18, allogeneic; combined data from 3 identical 
experiments. (E) FoxP3+ T cells in the spleen, as derived from donor BM-derived T cells, are shown 
as a percentage of all donor BM-derived CD45.1+CD4+ T cells on day 28 after allogeneic and syn-
geneic BMT. P = NS. n = 14, syngeneic; n = 23, allogeneic; combined data from 2 to 4 identical 
experiments. (D and E) Dots represent individual animals, and horizontal bars indicate the mean.
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indicating  a  effector  memory 
T cell phenotype, with a minor-







Donor alloreactive T cells have a 




B6  and  BALB/c mice  with  B6 
Thy1.1  splenic  T  cells  and  B6 
CD45.1+ TCD-BM. We observed 
a  peak  in  donor  alloactivated 































Alloreactive T cells require FasL and TRAIL to mediate tGVHD. (A) BM-derived CD4+CD8+ (DP) thy-
mocytes in recipients of B6 CD45.1 TCD-BM with or without 0.25 × 106 B6 versus B6.KO (deficient for 
cytolytic molecules) donor T cells on day 28. BM only, n = 18; WT T cells, n = 21; gld (FasL deficient), 
n = 8; Trail–/–, n = 8; gld/Trail–/–, n = 7; gld/Trail–/–Tnf–/–, n = 6; Pfp–/–, n = 12; Tnf–/–, n = 12; Ifng–/–, n = 16; 
combined data from 2 independent experiments. (B) Experiment as in A with 0.5 × 106 donor T cells. BM 
only, n = 22; WT T cells, n = 20; gld, n = 13; Trail–/–, n = 13; gld/Trail–/–Tnf–/–, n = 13; Pfp–/–, n = 12; Ifng–/–, 
n = 9; combined data from 2 to 3 independent experiments. (A and B) *P < 0.05, **P < 0.01 versus WT. 
(C) Thymic architecture of thymus sections from A were analyzed (H&E, day 28). Representative sections 
are shown. Original magnification, ×50. n = 5/group. (D) Total thymocyte counts in mice that received B6 
BM with or without 0.25 × 106 CD5+ B6 WT CD4, WT CD8, Trail–/– CD4, Trail–/– CD8, gld CD4, or gld CD8 
T cells. Symbols represent individual animals (mean ± SEM). *P < 0.05. n = 6–7/group. (E) Absolute num-
bers of BM-derived CD45.1+CD4+CD8+ thymocytes in lpr (Fas receptor deficient) and WT B6 recipients on 
day 28. Symbols represent individual animals (mean ± SEM). n = 8/group. **P < 0.01 versus correspond-
ing WT controls. (F) Total thymocytes in recipients of lpr or WT B6 TCD-BM and T cells on day 28. Dots 
represent individual animals. Horizontal bars indicate the mean (A, B, and F). n = 8–10/group.
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Donor alloreactive T cells require FasL and TNF-related apoptosis-induc-



































Soluble DR5 agonists are sufficient to damage the thymus after allo-BMT in 5×106 B6 CD45.1 + TCD-BM only → BALB/c (8.5 Gy) mice. Recipi-
ents were treated with 200 μg hamster IgG control antibody or DR5-1 agonistic antibody i.p. on days –1, 1, 3, and 5 peritransplant (A–E) or 
on days 10, 12, 14, and 16 after transplant (F–J). Recipients were analyzed at day 28 after transplant. Symbols represent individual animals 
(mean ± SEM). *P < 0.05, **P < 0.01 versus hamster IgG; combined data from 2 independent experiments. (A) Total thymocytes and (B) donor 
BM-derived CD45.1+CD4+CD8+ (DP) thymocytes. DR5-1, n = 11; hamster IgG, n = 15. (C) Total BM cells. n = 4–5/group. (D) Donor LSK cells 
from the BM. n = 4–5/group. (E) Donor splenic CD45.1+CD3ε+ T cells. DR5-1, n = 11; hamster IgG, n = 15. (F) Total thymocytes and (G) donor 
BM-derived CD45.1+CD4+CD8+ (DP) thymocytes. DR5-1, n = 5/group. (H) Total BM cells. n = 5/group. (I) Donor LSK cells from the BM. n = 5/ 
group. (J) Donor splenic CD45.1+CD3ε+ T cells. n = 5/group. (K) Mice were transplanted as above. Thymi from recipients of hamster IgG con-
trol antibody only were harvested at day 28, stained with anti-DR5 antibody, and gated for donor CD45.1+ thymocytes subsets (CD4–CD8–, 
CD4+CD8+, CD4+CD8–, and CD4–CD8+) as shown. The percentage of cells that are DR5 positive was determined based on an isotype control 
gate set at less than 0.25% positive. n = 5/group. Horizontal bars indicates the mean. DN, CD4+CD8+ double negative.
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Both CD4 and CD8 cells require FasL to mediate tGVHD, but 








Donor alloreactive T cells damage host-derived thymic 





















Soluble DR5 agonists are sufficient to damage the thymus 
after TCD allo-BMT. We  further  studied  the  role  of 
TRAIL in mediating thymic damage after transplant 























tGVHD causes damage to the thymic stroma, loss of thymic epithelial cells, and 
cortical thinning. (A) CD45– thymic stromal cell subsets were assessed by flow 
cytometry in allo-BMT recipients of TCD-BM with or without WT, Trail–/–, gld, 
or gld/Trail–/– T cells. Absolute numbers are displayed (mean ± SEM). TCD-
BM–only group, n = 9; WT T cells, n = 11; gld T cells, n = 10; Trail–/– T cells, 
n = 12; gld/Trail–/– T cells, n = 5. Combined data from 2 identical experiments. 
Endothelial cells, CD45–CD31+MHC class IIdim; fibroblasts, CD45–PDGFR1+MHC 
class IIneg; cTECs, CD45–CD31–MHC class IIint/hiUEA-1–; mTECs, CD45–CD31–
MHC class IIint/hiUEA-1+. *P < 0.05, **P < 0.01 versus WT T cells. (B) Repre-
sentative paraffin-fixed thymus sections from the groups that received TCD-BM 
with or without 0.25 × 106 WT, Trail–/–, gld, or gld/Trail–/– T cells were stained for 
K8–positive (red) cortical and K5–positive (green) medullary regions and ana-
lyzed by confocal microscopy at day 28 after transplant. Dotted lines indicate the 
corticomedullary junction. Solid lines indicate cortical thickness. Original magnifi-
cation, ×120. Representative images are shown (n = 2–3/group). (C) Experiment 
was performed as in B. Three paraffin-fixed thymus sections per thymus, spaced 
50 μm apart in each organ, were stained with K5 and K8 antibody and analyzed 
by confocal microscopy to quantitatively analyze total, medullary, and cortical 
areas. Averaged percent cortical area (mean ± SEM) was then determined as a 
fraction of total area. Symbols indicate individual animals. BM-only group, n = 5; 
WT and gld/Trail–/– groups; n = 8–9; combined data from 2 identical experiments. 
*P < 0.05 versus BM only.
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Donor alloreactive T cells damage thymic medullary and cortical epi-




















Donor alloreactive T cells and tGVHD cause cortical thinning in the thy-















Thymic stromal cells upregulate Fas and DR5 and downregulate cas-











Thymic stromal cells upregulate the death receptors Fas and DR5 and 
downregulate the antiapoptotic protein cFLIP, upon exposure to radia-
tion. Nontransplanted BALB/c mice were lethally irradiated (XRT) (8.5 
Gy), and CD45– thymic stromal cell subsets were analyzed for Fas and 
DR5 on days 1 and 3 (A) and intracellular cFLIP expression on days 
0, 1, 3, and 6 (B) by flow cytometry. On day 0, mice were analyzed 
4–6 hours after exposure (mean ± SEM). Nonirradiated BALB/c mice 
served as controls. *P < 0.05, **P < 0.001 versus control; combined 
data from 2–3 identical experiments. Gating for percentage of expres-
sion was based on isotype controls, with limits set at 2%. n = 5–13/
group for DR5 and Fas expression; n = 15–17/group for cFLIP expres-
sion; combined results from 2 to 3 identical experiments.
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Both canonical T cell thymus-trafficking molecules and T cell gut-traffick-

























WT CD4 T cells out-compete Itgb7–/– and Psgl1–/– CD4 T cells in early 
trafficking to spleen and thymus. To distinguish whether the decrease 
Figure 7
Alloreactive T cells require various homing molecules and costimulatory/inhibitory molecules to mediate tGVHD. (A) Allo-BMT and analysis was 
done as in Figure 3A. Dots represent individual animals. *P < 0.05, **P < 0.001 versus WT. BM only, n = 15; WT T cells, n = 17; Ccr9–/–, n = 15; 
Sell–/–, n = 7; Itgae–/–, n = 6; Itgb7–/–, n = 21; Psgl1–/–, n = 16; Ccr2–/–, n = 8; Cxcr3–/–, n = 6. Combined from 1 to 3 experiments. (B) For the β7 
subunit, CFSE+CD45.1+CD4+ T cells were mixed 1:1 with CFSE+CD45.2+CD4+ WT or CFSE+CD45.2+CD4+ Itgb7–/– B6 T cells, and 5 × 106 mixed 
cells were transferred into irradiated BALB/c. Infiltrating donor T cells on day 7 are shown. n = 5/group. For PSGL-1, CD45.1+CFSE B6 T were 
mixed 1:1 with CFSE+CD45.2+ WT T or CFSE+CD45.2 Psgl1–/– B6 T cells and adoptively transferred. Recovered CD4+ T cells are shown. n = 10/ 
group (mean ± SEM). *P < 0.05, **P < 0.001 for percentage of CD45.1– B6.KO versus B6.WT T cells. (C) Allo-BMT and analysis was done as 
in Figure 3A. Squares represent individual animals. *P < 0.05, **P < 0.001 versus WT. BM only, n = 8; WT T cells, n = 13; Icos–/–, n = 5; Ox40–/–, 
n = 7; Gitr–/–, n = 7; Ceacam1–/–, n = 6; Ceacam1-Tg, n = 6; combined from 1 to 2 experiments. (D) Numbers of BM-derived CD45.1+CD4+CD8+ 
(DP) thymocytes (mean ± SEM) in recipients of 5 × 106 B6 CD45.1 TCD-BM with or without 3.2 × 106 Teffs plus 0.8 × 106 Tregs. *P < 0.05 ver-
sus WT Tregs plus WT Teffs; recipients of TCD-BM only and recipients of Ox40–/– Tregs plus WT B6 Teffs, n = 5; all other groups, n = 7/group. 
Horizontal bars indicate the mean.
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Ox40 and carcinoembryonic antigen-associated cell adhesion molecule 1 
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